Why the study?
Whether Sini San (SNS) is effective in treating hyperprolactinemia combined with liver depression and its underlying mechanisms were unknown.
Population
Animal models and rat pituitary tumor MMQ cells
Comparison
Sini San (SNS) administration
Design
Preclinical network pharmacology, molecular docking, metabolomics, and experimental validation study
Key result
Sini San improved depressive-like behaviors, regulated sex hormone levels, and inhibited prolactin secretion in hyperprolactinemia models with liver-depression by regulating lipid metabolism.
Authors
Loading...
Hypothesis-generating for Sini San in hyperprolactinemia; prospective human trials needed before clinical adoption.
Sini San demonstrates therapeutic potential for hyperprolactinemia with liver-depression in preclinical models by regulating lipid metabolism and key targets including AKT1, TNF, and IL6.
Xu et al. (2024) studied Hyperprolactinemia with liver-depression. Sini San (SNS) was evaluated on Depressive behaviors, sex hormone levels, ovarian morphology, and prolactin release. Sini San improved depressive-like behaviors, regulated sex hormone levels, and inhibited prolactin secretion in hyperprolactinemia models with liver-depression by regulating lipid metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: